Collegium Pharmaceutical
COLL
eBay
EBAY
Halozyme Therapeutics
HALO
SilverCrest Metals
SILV
Workday
WDAY
(Q2)Jun 30, 2017 | (FY)Dec 31, 2016 | (Q4)Dec 31, 2016 | (Q3)Sep 30, 2016 | (Q2)Jun 30, 2016 | (Q1)Mar 31, 2016 | (FY)Dec 31, 2015 | (Q4)Dec 31, 2015 | (Q3)Sep 30, 2015 | (Q2)Jun 30, 2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.52%5.04M | 2.96%20.73M | 0.07%5.52M | 5.12%5.48M | -5.06%4.92M | 13.93%4.8M | 5.06%20.13M | 39.45%5.52M | 8.69%5.22M | -3.98%5.18M |
Operating revenue | 2.52%5.04M | 2.96%20.73M | 0.07%5.52M | 5.12%5.48M | -5.06%4.92M | 13.93%4.8M | 5.06%20.13M | 39.45%5.52M | 8.69%5.22M | -3.98%5.18M |
Cost of revenue | -3.00%3.17M | 5.05%13.09M | 2.33%3.3M | 6.65%3.48M | 3.65%3.27M | 7.84%3.05M | -0.68%12.46M | 13.14%3.22M | 7.41%3.26M | -0.25%3.15M |
Gross profit | 13.43%1.88M | -0.43%7.63M | -3.09%2.23M | 2.56%2.01M | -18.57%1.65M | 26.39%1.75M | 15.96%7.67M | 106.84%2.3M | 10.89%1.96M | -9.25%2.03M |
Operating expense | 2.62%1.65M | -2.41%6.57M | -0.76%1.69M | -5.75%1.57M | -4.36%1.6M | 1.19%1.7M | -21.52%6.73M | -3.13%1.7M | -11.74%1.67M | -29.70%1.68M |
Selling and administrative expenses | 2.62%1.65M | -2.41%6.57M | -0.76%1.69M | -5.75%1.57M | -4.36%1.6M | 1.19%1.7M | -21.52%6.73M | -3.13%1.7M | -11.74%1.67M | -29.70%1.68M |
Operating profit | 360.00%230K | 13.78%1.07M | -9.73%538K | 51.05%432K | -85.88%50K | 115.00%45K | 147.66%936K | 192.26%596K | 323.44%286K | 340.82%354K |
Net non-operating interest income expense | 0 | 22.86%-27K | 50.00%-4K | 22.22%-7K | 11.11%-8K | 11.11%-8K | 14.63%-35K | 20.00%-8K | 10.00%-9K | 10.00%-9K |
Non-operating interest expense | --0 | -22.86%27K | -50.00%4K | -22.22%7K | -11.11%8K | -11.11%8K | -14.63%35K | -20.00%8K | -10.00%9K | -10.00%9K |
Other net income (expense) | 0.00%4K | 25.00%30K | -54.55%5K | 200.00%15K | 0.00%4K | 50.00%6K | -33.33%24K | -50.00%11K | -28.57%5K | 233.33%4K |
Gain on sale of security | 0.00%4K | 25.00%30K | -54.55%5K | 200.00%15K | --4K | 50.00%6K | -33.33%24K | --11K | --5K | ---- |
Special income (charges) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --4K |
Income before tax | 408.70%234K | 15.46%1.07M | -10.02%539K | 56.03%440K | -86.82%46K | 114.10%43K | 146.98%925K | 194.48%599K | 315.27%282K | 318.13%349K |
Income tax | 135.71%10K | -1,508.70%-324K | -1,906.25%-289K | 53.13%-15K | -255.56%-28K | -61.90%8K | -28.13%23K | -15.79%16K | -100.00%-32K | 63.64%18K |
Net income | 202.70%224K | 54.32%1.39M | 42.02%828K | 44.90%455K | -77.64%74K | 110.74%35K | 145.08%902K | 189.28%583K | 373.04%314K | 293.57%331K |
Net income continuous Operations | 202.70%224K | 54.32%1.39M | 42.02%828K | 44.90%455K | -77.64%74K | 110.74%35K | 145.08%902K | 189.28%583K | 373.04%314K | 293.57%331K |
Minority interest income | ||||||||||
Net income attributable to the parent company | 202.70%224K | 54.32%1.39M | 42.02%828K | 44.90%455K | -77.64%74K | 110.74%35K | 145.08%902K | 189.28%583K | 373.04%314K | 293.57%331K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 202.70%224K | 54.32%1.39M | 42.02%828K | 44.90%455K | -77.64%74K | 110.74%35K | 145.08%902K | 189.28%583K | 373.04%314K | 293.57%331K |
Basic earnings per share | 200.00%0.06 | 57.14%0.33 | 42.86%0.2 | 57.14%0.11 | -75.00%0.02 | 114.29%0.01 | 145.65%0.21 | 193.33%0.14 | 333.33%0.07 | 300.00%0.08 |
Diluted earnings per share | 200.00%0.06 | 57.14%0.33 | 42.86%0.2 | 57.14%0.11 | -75.00%0.02 | 114.29%0.01 | 145.65%0.21 | 193.33%0.14 | 333.33%0.07 | 300.00%0.08 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |